1.5 Abstract in rivista

1.5 Abstract in rivista: [2371] Home page tipologia

Sfoglia

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 1.241 a 1.260 di 2.371

Antitumour activity of bortezomib-pegylated liposomal doxorubicine association: Results of an ongoing study in multiple myeloma patients.

2006 Braccalenti, G.; Ferrara, P; Gubbiotti, M; Cerroni, P; Emili, R; Morandi, Mg; Pace, R; Liberati, Anna Marina

Philadelphia chromosome (Ph') secondary clones in chronic myeloid leukemia (CML) are not indicative of resistance to IFNa- or imatinib-based treatment regimens.

2006 Falchi, L; Prontera, P; Luzi, D; Festuccia, V; Emili, R; Gottardi, E; Donti, E; Liberati, Anna Marina

Persistent molecular remission in patients treated with imatinib-IFNa combination or imatinib monotherapy

2006 Schippa, M; Gottardi, E; Luzi, D; Falchi, L; Emili, R; Angeletti, I; Desantis, G; Gentileschi, E; Cerroni, P; Liberati, Anna Marina

Patterns of clonal evolution in Ph'-positive chronic myelogenous leukemia (CML) during chronic phase: Overall incidence, type, multiplicity, development time, effect on subsequent genetic instability, sokal risk, type of bcr/abl transcript and hematological evolution.

2006 Luzi, D; Falchi, L; Emili, R; Angeletti, I; Prontera, P; Venti, G; Bassetti, A; Gubbiotti, M; Capparella, V; Gentileschi, E; Donti, E; Liberati, Anna Marina

Rituximab as adjuvant to dose-dense and high dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) as first line treatment in stage III-IV diffuse large B-Cell lymphoma (DLBCL) at poor prognosis: Final analysis of phase II GIMURELL trial.

2006 Vitolo, U; Cabras, Mg; Rossi, G; Liberati, Anna Marina

A prospective, randomized, phase III study of melphalan 200 mg/m(2) (MEL200) versus melphalan 100 mg/m(2) (MEL100) in newly diagnosed myeloma patients.

2006 Palumbo, A; Bringhen, S; Petrucci, Mt; Falcone, A; Liberati, Anna Marina

Impact of complete kariotypic remission (CKR) and sokal risk on overall survival in chronic myelogenous leukemia (CML) patients: A monocentric experience.

2006 Falchi, L; Schippa, M; Luzi, D; Emili, R; Festuccia, V; Giugliano, E; Ardisia, C; Rauco, A; Pace, R; Doriti, E; Liberati, Anna Marina

Clinical and molecular results of the multicenter randomized GITMO-IIL, trial in poor risk follicular lymphoma (FL) at diagnosis: Rituximab-supplemented high-dose sequential chemotherapy (R-HDS) is superior to CHOP-R in molecular remissions rate, EFS and PFS.

2006 Ladetto, M; de Marco, F; Benedetti, F; Vitolo, U; Patti, C; Rambaldi, A; Liberati, Anna Marina; Et, All

Factors affecting the yield peripheral blood stem cells

2008 Schippa, M; Siepi, D; Falchi, L; Festuccia, V; Gunnellini, M; Martiniani, R; Angeletti, I; Pace, R; Liberati, Anna Marina

AUTOLOGOUS STEM CELL TRANSPLANTATION FOR PERIPHERAL T-CELL LYMPHOMA, A SINGLE-CENTRE EXPERIENCE

2008 Luzi, D; Falchi, L; Listorti, C; Gunnellini, M; Angeletti, I; Emili, R; Liberati, Anna Marina

Factors that influence early and late haemopoietic reconstitution after autotransplantation with peripheral blood stem cells

2008 Falchi, L; Siepi, D; Schippa, M; Gunnellini, M; Festuccia, V; Martiniani, R; Angeletti, I; Capparella, V; Liberati, Anna Marina

PAD-MEL100-LP-L in Elderly Untreated Myeloma Patients

2009 Palumbo, A; Falco, P; Gay, F; Montefusco, V; Crippa, C; Patriarca, F; Caltagirone, S; Liberati, Anna Marina; Et, All

A Phase III Study of MEL200 Versus MEL100 in Newly Diagnosed Myeloma Young Patients

2009 Boccadoro, M; Bringhen, S; Petrucci, Mt; Falcone, A; Liberati, Anna Marina; Et, All

A recent update of 3 consecutive prospective trials with high-dose therapy and autograft, without or with rituximab, as primary treatment for advanced-stage follicular lymphoma shows a sizeable group of patients surviving in continuous complete remission

2010 Tarella, C; Ladetto, M; Benedetti, F; Vitolo, U; Pulsoni, A; Patti, C; Callea, V; Rambaldi, A.; Piccin, A; Devizzi, L.; Musso, M; Iannitto, E; Spedini, P; Liberati, Anna Marina

VENOUS THROMBOEMBOLISM RECURRENCE AFTER A FIRST EPISODE OF PROVOKED VENOUS THROMBOSIS DUE TO A TRANSIENT RISK FACTOR. A SYSTEMATIC REVIEW OF THE LITERATURE

2010 Filippucci, E.; Kearon, C.; Marcucci, M.; Pengo, V.; Siragusa, S.; Palareti, G.; Iorio, Alfonso

ANTITHROMBOTIC PROPHYLAXIS IN ELDERLY PATIENTS ATRIAL FIBRILLATION ADMITTED TO INTERNAL MEDICINE WARDS IN ITALY: ADHERENCE TO GUIDELINES

2010 Iorio, Alfonso; Marcucci, M.; Pasina, L.; Marengoni, A.; Salerno, F.; Corrao, S.; Nobili, A.; Mannucci, P. M.

DOES THE CLINICAL PRESENTATION AND EXTENT OF VENOUS THROMBOSIS PREDICT LIKELIHOOD AND TYPE OF RECURRENCE? A PATIENT LEVEL META-ANALYSIS OF 2,554 UNSELECTED PATIENTS AFTER A FIRST THROMBOSIS

2010 Marcucci, M.; Tosetto, A.; Baglin, T.; Douketis, J.; Cushman, M.; Eichinger, S.; Palareti, G.; Poli, D.; Tait, C.; Iorio, Alfonso

D-DIMER TO PREDICT RECURRENCE AFTER A FIRST EPISODE OF UNPROVOKED VENOUS THROMBOEMBOLISM: COMPARISON OF AGGREGATE AND INDIVIDUAL PATIENT DATA META-ANALYSIS

2010 Marcucci, M.; Douketis, J.; Tosetto, A.; Baglin, T.; Cushman, M.; Eichinger, S.; Palareti, G.; Poli, D.; Tait, C.; Iorio, Alfonso

CLOTTING FACTOR CONCENTRATES GIVEN TO PREVENT BLEEDING AND BLEEDING-RELATED COMPLICATIONS IN PEOPLE WITH HAEMOPHILIA A OR B

2010 Marchesini, E.; Marcucci, M.; Stobart, K.; Chan, A.; Iorio, Alfonso

A. TRANSITION TO A WEB-BASED ARCHITECTURE OF THE ITALIAN HEMOPHILIA REGISTRY NETWORK

2010 Oliovecchio, E.; Marchesini, E.; Rodorigo, G.; Marietta, M.; Di Minno, G.; Perricone, C.; Macchi, S.; Castaman, G.; Morfini, M.; Iorio, Alfonso

Titolo	Data di pubblicazione	Autore(i)
Antitumour activity of bortezomib-pegylated liposomal doxorubicine association: Results of an ongoing study in multiple myeloma patients.	2006	Braccalenti, G.; Ferrara, P; Gubbiotti, M; Cerroni, P; Emili, R; Morandi, Mg; Pace, R; Liberati, Anna Marina
Philadelphia chromosome (Ph') secondary clones in chronic myeloid leukemia (CML) are not indicative of resistance to IFNa- or imatinib-based treatment regimens.	2006	Falchi, L; Prontera, P; Luzi, D; Festuccia, V; Emili, R; Gottardi, E; Donti, E; Liberati, Anna Marina
Persistent molecular remission in patients treated with imatinib-IFNa combination or imatinib monotherapy	2006	Schippa, M; Gottardi, E; Luzi, D; Falchi, L; Emili, R; Angeletti, I; Desantis, G; Gentileschi, E; Cerroni, P; Liberati, Anna Marina
Patterns of clonal evolution in Ph'-positive chronic myelogenous leukemia (CML) during chronic phase: Overall incidence, type, multiplicity, development time, effect on subsequent genetic instability, sokal risk, type of bcr/abl transcript and hematological evolution.	2006	Luzi, D; Falchi, L; Emili, R; Angeletti, I; Prontera, P; Venti, G; Bassetti, A; Gubbiotti, M; Capparella, V; Gentileschi, E; Donti, E; Liberati, Anna Marina
Rituximab as adjuvant to dose-dense and high dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) as first line treatment in stage III-IV diffuse large B-Cell lymphoma (DLBCL) at poor prognosis: Final analysis of phase II GIMURELL trial.	2006	Vitolo, U; Cabras, Mg; Rossi, G; Liberati, Anna Marina
A prospective, randomized, phase III study of melphalan 200 mg/m(2) (MEL200) versus melphalan 100 mg/m(2) (MEL100) in newly diagnosed myeloma patients.	2006	Palumbo, A; Bringhen, S; Petrucci, Mt; Falcone, A; Liberati, Anna Marina
Impact of complete kariotypic remission (CKR) and sokal risk on overall survival in chronic myelogenous leukemia (CML) patients: A monocentric experience.	2006	Falchi, L; Schippa, M; Luzi, D; Emili, R; Festuccia, V; Giugliano, E; Ardisia, C; Rauco, A; Pace, R; Doriti, E; Liberati, Anna Marina
Clinical and molecular results of the multicenter randomized GITMO-IIL, trial in poor risk follicular lymphoma (FL) at diagnosis: Rituximab-supplemented high-dose sequential chemotherapy (R-HDS) is superior to CHOP-R in molecular remissions rate, EFS and PFS.	2006	Ladetto, M; de Marco, F; Benedetti, F; Vitolo, U; Patti, C; Rambaldi, A; Liberati, Anna Marina; Et, All
Factors affecting the yield peripheral blood stem cells	2008	Schippa, M; Siepi, D; Falchi, L; Festuccia, V; Gunnellini, M; Martiniani, R; Angeletti, I; Pace, R; Liberati, Anna Marina
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR PERIPHERAL T-CELL LYMPHOMA, A SINGLE-CENTRE EXPERIENCE	2008	Luzi, D; Falchi, L; Listorti, C; Gunnellini, M; Angeletti, I; Emili, R; Liberati, Anna Marina
Factors that influence early and late haemopoietic reconstitution after autotransplantation with peripheral blood stem cells	2008	Falchi, L; Siepi, D; Schippa, M; Gunnellini, M; Festuccia, V; Martiniani, R; Angeletti, I; Capparella, V; Liberati, Anna Marina
PAD-MEL100-LP-L in Elderly Untreated Myeloma Patients	2009	Palumbo, A; Falco, P; Gay, F; Montefusco, V; Crippa, C; Patriarca, F; Caltagirone, S; Liberati, Anna Marina; Et, All
A Phase III Study of MEL200 Versus MEL100 in Newly Diagnosed Myeloma Young Patients	2009	Boccadoro, M; Bringhen, S; Petrucci, Mt; Falcone, A; Liberati, Anna Marina; Et, All
A recent update of 3 consecutive prospective trials with high-dose therapy and autograft, without or with rituximab, as primary treatment for advanced-stage follicular lymphoma shows a sizeable group of patients surviving in continuous complete remission	2010	Tarella, C; Ladetto, M; Benedetti, F; Vitolo, U; Pulsoni, A; Patti, C; Callea, V; Rambaldi, A.; Piccin, A; Devizzi, L.; Musso, M; Iannitto, E; Spedini, P; Liberati, Anna Marina
VENOUS THROMBOEMBOLISM RECURRENCE AFTER A FIRST EPISODE OF PROVOKED VENOUS THROMBOSIS DUE TO A TRANSIENT RISK FACTOR. A SYSTEMATIC REVIEW OF THE LITERATURE	2010	Filippucci, E.; Kearon, C.; Marcucci, M.; Pengo, V.; Siragusa, S.; Palareti, G.; Iorio, Alfonso
ANTITHROMBOTIC PROPHYLAXIS IN ELDERLY PATIENTS ATRIAL FIBRILLATION ADMITTED TO INTERNAL MEDICINE WARDS IN ITALY: ADHERENCE TO GUIDELINES	2010	Iorio, Alfonso; Marcucci, M.; Pasina, L.; Marengoni, A.; Salerno, F.; Corrao, S.; Nobili, A.; Mannucci, P. M.
DOES THE CLINICAL PRESENTATION AND EXTENT OF VENOUS THROMBOSIS PREDICT LIKELIHOOD AND TYPE OF RECURRENCE? A PATIENT LEVEL META-ANALYSIS OF 2,554 UNSELECTED PATIENTS AFTER A FIRST THROMBOSIS	2010	Marcucci, M.; Tosetto, A.; Baglin, T.; Douketis, J.; Cushman, M.; Eichinger, S.; Palareti, G.; Poli, D.; Tait, C.; Iorio, Alfonso
D-DIMER TO PREDICT RECURRENCE AFTER A FIRST EPISODE OF UNPROVOKED VENOUS THROMBOEMBOLISM: COMPARISON OF AGGREGATE AND INDIVIDUAL PATIENT DATA META-ANALYSIS	2010	Marcucci, M.; Douketis, J.; Tosetto, A.; Baglin, T.; Cushman, M.; Eichinger, S.; Palareti, G.; Poli, D.; Tait, C.; Iorio, Alfonso
CLOTTING FACTOR CONCENTRATES GIVEN TO PREVENT BLEEDING AND BLEEDING-RELATED COMPLICATIONS IN PEOPLE WITH HAEMOPHILIA A OR B	2010	Marchesini, E.; Marcucci, M.; Stobart, K.; Chan, A.; Iorio, Alfonso
A. TRANSITION TO A WEB-BASED ARCHITECTURE OF THE ITALIAN HEMOPHILIA REGISTRY NETWORK	2010	Oliovecchio, E.; Marchesini, E.; Rodorigo, G.; Marietta, M.; Di Minno, G.; Perricone, C.; Macchi, S.; Castaman, G.; Morfini, M.; Iorio, Alfonso

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 1.241 a 1.260 di 2.371

Legenda icone

file ad accesso aperto
file disponibili sulla rete interna
file disponibili agli utenti autorizzati
file disponibili solo agli amministratori
file sotto embargo
nessun file disponibile

Scopri

Accesso al fulltext

no fulltext2371

IRIS - Res&Arch Institutional Research Information System - Research & Archive